ClinicalTrials.gg
CompletedNCT02574520PERSISTUpdated Jul 13, 2021Results posted

Trial of Extended Release Bupivacaine for Pain Relief After Surgery

A Phase 3 interventional study of SABER-Bupivacaine (Part 1) and SABER-Bupivacaine (Part 2) in Post Operative Pain, sponsored by Durect. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-13.

Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
399
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
6th of 364
399 · median 70
Started
2015
with 24 others
Phase 3
42 of 364
2 open now
Registered
78th of 364
by date

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 6th largest by enrollment, is one of 25 that started in 2015, is one of 42 in phase 3, and was the 78th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a research study of SABER® -Bupivacaine, an experimental medication designed to reduce pain for up to 3 days after surgery. Given once by the surgeon at the end of surgery, SABER® - Bupivacaine delivers a locally-acting pain reliever directly to the surgical wound.

The purpose of this study is to measure how well it works in reducing pain after laparoscopic cholecystectomy (surgery to remove the gall bladder) and to investigate the safety of SABER®-Bupivacaine (its side effects).

03

Conditions studied

  • Post Operative Pain

Browse trials for

Keywords

  • Post-operative pain
  • non-opioid analgesic
  • opioid reduction
  • laparoscopic cholecystectomy
  • laparoscopic surgery
  • bupivacaine
  • extended release
  • locally acting analgesic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective outpatient laparoscopic cholecystectomy using a conventional 4-port laparoscopic procedure.
  • Must be able and willing to provide written , complete trial-related procedures, and communicate with the trial staff.
  • Males and females 18 years of age or older.
  • ASA Class I, II, or III.
  • Patients of must agree to use a medically acceptable method of to prevent pregnancy for the duration of their participation in the trial.
  • Must be living close enough to the investigative site to attend the four scheduled follow-up clinic visits.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing females.
  • Patients with absolute or relative to laparoscopic cholecystectomy.
  • Patients with prior midline abdominal surgery who are at risk for adhesions that may complicate laparoscopic cholecystectomy and/or accurate pain assessments.
  • Patients requiring emergency surgery or urgent surgery (fewer than 5 days between screening and surgery).
  • Patients with a pre-planned overnight stay or pre-planned hospital admission.
  • Patients scheduled for single incision, mini trocars, natural orifice transluminal endoscopic surgery (NOTES), robotic laparoscopic procedures, or any procedure (other than cholangiograms and minimal adhesiolysis) in addition to laparoscopic cholecystectomy.
  • Patients with known to amide local anesthetics such as bupivacaine.
  • Patients with acute pain that is not due to cholecystitis.
  • Patients with a history of chronic pain unrelated to gallbladder disease.
  • Patients with ongoing depression or psychosis.
  • Patients undergoing long-term treatment with opioids or other analgesics, including acetaminophen, NSAIDs, anticonvulsants (gabapentin or pregabalin), and antidepressants (SSRIs, SNRIs, and tricyclics), but not including daily low-dose aspirin.
  • Patients who are being treated chronically with systemic or who will require peri-operative corticosteroids because of adrenal insufficiency (inhalational or topical corticosteroids are permitted).
  • Patients who may be unsuitable for opioid administration (such as sensitivity [e.g., history of severe nausea and vomiting] hypersensitivity, known history of abuse or addiction, or unwillingness to take prescribed rescue opioids).
  • Use of anticoagulants and antiplatelet drugs (with exception of low dose aspirin) in the 1 week prior to surgery.
  • Patients who are incapable of operating the electronic diary.
  • Patients participating in any other trial with an drug or device concurrently or less than 30 days prior to surgery for this trial.
  • Patients who, in the Investigator's opinion, should not participate in the trial or may not be capable of following the trial procedures for any reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
399 participants (actual)

Study arms

  • Placebo comparator
    Part 1

    SABER-Bupivacaine and Saline Placebo

    Drug: SABER-Bupivacaine (Part 1) · Drug: Saline Placebo

  • Active comparator
    Part 2

    SABER-Bupivacaine and Bupivacaine HCl

    Drug: SABER-Bupivacaine (Part 2) · Drug: Bupivacaine HCl

Interventions

  • DrugSABER-Bupivacaine (Part 1)

    5 ml once at end of surgery

    Also known as: POSIMIR® bupivacaine solution

  • DrugSABER-Bupivacaine (Part 2)

    5 ml once at end of surgery

    Also known as: POSIMIR® bupivacaine solution

  • DrugSaline Placebo

    5 ml once at end of surgery

    Also known as: placebo

  • 0.5%, 15 ml, once at end of surgery

06

What researchers measure

Primary outcomes

  1. Pain Intensity on Movement From 0-48 Hours Post-Treatment

    A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 13 planned time points from 0 to 48 hours post-treatment. The values reported are mean pain scores for each treatment group.

    Time frame: Assessed from 0 to 48 hours post-dose, summary measure (see description) reported.

Secondary outcomes

  1. Pain Intensity Using the NPRS-11 With Movement

    A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 17 planned time points from 0 to 72 hours post-treatment. The values reported are mean pain scores for each treatment group.

    Time frame: Assessed from 0 to 72 hours post-dose, summary measure (see description) reported.

  2. Total IV Morphine-equivalent Dose of Rescue Opioids

    IV morphine-equivalent dose

    Time frame: 0-72 hrs. post dose (after surgery)

  3. Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score

    Score of Integrated Analgesia (SIA) is a composite endpoint that integrates pain assessment scores with opioid use over various collections of timepoints by ranking the pain score and the opioid use separately across treatments. After the scores are computed the means are calculated across time points to provide a single overall treatment effect. The composite SIA score ranges from -200 to 200 with -200 being the best case and 200 the worst case.

    Time frame: 0 to 72 hours

  4. Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours

    Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl

    Time frame: From PACU Discharge to 72 Hours post-treatment

  5. Time to First Opioid Rescue Medication Use After Discharge From the PACU

    Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl

    Time frame: From PACU Discharge to 72 Hours post-treatment

  6. Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)

    mPADSS is a tool used to determine eligibility for discharge from the PACU after ambulatory surgery. It includes an assessment of parameters such as vital signs, activity level, nausea/vomiting, pain, and surgical bleeding. For this trial, evaluation of eligibility for PACU discharge by mPADSS has been slightly modified to provide a standardized means of assessing eligibility for PACU discharge across multiple investigative sites and also ensures that nonmedical complications, such as a missing ride home, do not interfere with evaluation of test drug effects.

    Time frame: From admission to discharge from PACU (Approximately 0 to 12 hours)

07

Results

Posted Jul 13, 2021

Participant flow

The study was conducted at 22 sites in the US. First subject was randomized on 17 November 2015. Study completion date was on 16 Aug 2017.

Participant flow — Overall Study
MilestoneSABER-Bupivacaine (Part 1)Saline Placebo (Part 1)SABER-Bupivacaine (Part 2)Bupivacaine HCL (Part 2)
Started4846153152
Dosed4646148148
Completed4646148144
Not completed2058
Withdrew: Not dosed2054
Withdrew: Adverse event0001
Withdrew: Withdrawal by subject0001
Withdrew: Other0002

Outcome measures

PrimaryPain Intensity on Movement From 0-48 Hours Post-Treatment

A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 13 planned time points from 0 to 48 hours post-treatment. The values reported are mean pain scores for each treatment group.

Time frame:
Assessed from 0 to 48 hours post-dose, summary measure (see description) reported.
Reported as:
Mean · score on a scale
Pain Intensity on Movement From 0-48 Hours Post-Treatment
score on a scalePart 2/SABER-BupivacainePart 2/Bupivacaine HCl
Pain Intensity on Movement From 0-48 Hours Post-Treatment5.55 ± 0.0655.87 ± 0.059
Statistical analysis
  • Part 2/SABER-Bupivacaine vs Part 2/Bupivacaine HCl · ANOVA · p = 0.124 · Mean difference (final values): -0.37 · 95% CI -0.84 to 0.10Least squares mean from the MMRM described in the Statistical Test of Hypothesis.
SecondaryPain Intensity Using the NPRS-11 With Movement

A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 17 planned time points from 0 to 72 hours post-treatment. The values reported are mean pain scores for each treatment group.

Time frame:
Assessed from 0 to 72 hours post-dose, summary measure (see description) reported.
Reported as:
Mean · score on a scale
Pain Intensity Using the NPRS-11 With Movement
score on a scalePart 1 and Part 2: SABER-BupivacainePart 2: Bupivacaine HCl
Pain Intensity Using the NPRS-11 With Movement4.94 ± 0.0495.40 ± 0.052
SecondaryTotal IV Morphine-equivalent Dose of Rescue Opioids

IV morphine-equivalent dose

Time frame:
0-72 hrs. post dose (after surgery)
Reported as:
Mean · IV morphine equivalent (mg)
Total IV Morphine-equivalent Dose of Rescue Opioids
IV morphine equivalent (mg)Part 1 and Part 2: SABER-BupivacainePart 2: Bupivacaine HCl
Total IV Morphine-equivalent Dose of Rescue Opioids21.4 ± 1.3722.6 ± 1.58
SecondaryComposite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score

Score of Integrated Analgesia (SIA) is a composite endpoint that integrates pain assessment scores with opioid use over various collections of timepoints by ranking the pain score and the opioid use separately across treatments. After the scores are computed the means are calculated across time points to provide a single overall treatment effect. The composite SIA score ranges from -200 to 200 with -200 being the best case and 200 the worst case.

Time frame:
0 to 72 hours
Reported as:
Mean · score on a scale
Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score
score on a scalePart 1 and Part 2: SABER-BupivacainePart 2: Bupivacaine HCl
Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score-17.3 ± 8.83-1.5 ± 9.33
SecondarySubjects Not Taking Rescue Medication From PACU Discharge to 72 Hours

Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl

Time frame:
From PACU Discharge to 72 Hours post-treatment
Reported as:
Number · participants
Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours
participantsPart 1 and Part 2: SABER-BupivacainePart 2: Bupivacaine HCl
Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours5742
SecondaryTime to First Opioid Rescue Medication Use After Discharge From the PACU

Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl

Time frame:
From PACU Discharge to 72 Hours post-treatment
Reported as:
Median · hours
Time to First Opioid Rescue Medication Use After Discharge From the PACU
hoursPart 1 and Part 2: SABER-BupivacainePart 2: Bupivacaine HCl
Time to First Opioid Rescue Medication Use After Discharge From the PACU5.5 (3.5 to 7.7)6.1 (3.3 to 9.0)
SecondaryTime to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)

mPADSS is a tool used to determine eligibility for discharge from the PACU after ambulatory surgery. It includes an assessment of parameters such as vital signs, activity level, nausea/vomiting, pain, and surgical bleeding. For this trial, evaluation of eligibility for PACU discharge by mPADSS has been slightly modified to provide a standardized means of assessing eligibility for PACU discharge across multiple investigative sites and also ensures that nonmedical complications, such as a missing ride home, do not interfere with evaluation of test drug effects.

Time frame:
From admission to discharge from PACU (Approximately 0 to 12 hours)
Reported as:
Median · hours
Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)
hoursPart 1 and Part 2: SABER-BupivacainePart 2: Bupivacaine HCl
Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)1.8 (1.8 to 1.9)1.9 (1.8 to 2.0)

Adverse events

Collected over Approximately 0-60 days after surgery (duration of time over which each participant was assessed).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SABER-Bupivacaine (Part 1)0/45 (0%)1/45 (2.2%)43/45 (95.6%)
Saline Placebo (Part 1)0/47 (0%)0/47 (0%)47/47 (100%)
SABER-Bupivacaine (Part 2)0/148 (0%)5/148 (3.4%)148/148 (100%)
Bupivacaine HCL (Part 2)0/148 (0%)3/148 (2%)146/148 (98.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventSABER-Bupivacaine (Part 1)Saline Placebo (Part 1)SABER-Bupivacaine (Part 2)Bupivacaine HCL (Part 2)
DizzinessNervous system disorders1/450/470/1480/148
Abdominal abscessInfections and infestations0/450/470/1481/148
Bile duct stoneHepatobiliary disorders0/450/471/1480/148
DehydrationMetabolism and nutrition disorders0/450/471/1480/148
GastritisGastrointestinal disorders0/450/470/1481/148
Hepatic enzyme increasedInvestigations0/450/471/1480/148
HypotensionVascular disorders0/450/471/1480/148
PancreatitisGastrointestinal disorders0/450/471/1480/148
Pancreatitis acuteGastrointestinal disorders0/450/470/1481/148
Post procedural bile leakInjury, poisoning and procedural complications0/450/471/1480/148
Most frequent other events
Showing 10 of 25
Most frequent other events
EventSABER-Bupivacaine (Part 1)Saline Placebo (Part 1)SABER-Bupivacaine (Part 2)Bupivacaine HCL (Part 2)
Post procedural contusionInjury, poisoning and procedural complications41/4533/47142/148110/148
Somnolence (Solicited)Nervous system disorders24/4522/4773/14865/148
Procedural painInjury, poisoning and procedural complications19/4521/4732/14835/148
Constipation (Solicited)Gastrointestinal disorders20/4519/4765/14858/148
Headache (Solicited)Nervous system disorders17/4515/4753/14849/148
NauseaNervous system disorders8/4511/4747/14851/148
Nausea (solicited)Nervous system disorders10/4515/4742/14845/148
Dizziness (Solicited)Nervous system disorders11/459/4738/14840/148
Pruritus (Solicited)Skin and subcutaneous tissue disorders5/4511/4731/14827/148
Dysgeusia (Solicited)Gastrointestinal disorders4/452/4731/14824/148

Baseline characteristics

All Enrolled Subjects (ITT population)

Age, Continuous
Age, Continuous(years)SABER-Bupivacaine (Part 1)Saline Placebo (Part 1)SABER-Bupivacaine (Part 2)Bupivacaine HCL (Part 2)Total
Mean46.0 ± 14.241.8 ± 12.845.5 ± 13.544.7 ± 13.944.8 ± 13.67
Sex: Female, Male
Sex: Female, Male(Participants)SABER-Bupivacaine (Part 1)Saline Placebo (Part 1)SABER-Bupivacaine (Part 2)Bupivacaine HCL (Part 2)Total
Female3129115117292
Male17173835107
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SABER-Bupivacaine (Part 1)Saline Placebo (Part 1)SABER-Bupivacaine (Part 2)Bupivacaine HCL (Part 2)Total
American Indian or Alaska Native00000
Asian225615
Native Hawaiian or Other Pacific Islander00000
Black or African American746926
White3940141135355
More than one race00000
Unknown or Not Reported00123
Region of Enrollment
Region of Enrollment(participants)SABER-Bupivacaine (Part 1)Saline Placebo (Part 1)SABER-Bupivacaine (Part 2)Bupivacaine HCL (Part 2)Total
United States4846153152399
08

Study locations

21 sites
  • Durect Study Site 04
    Florence, Alabama 35360, United States
  • Durect Study Site 03
    Sheffield, Alabama 35660, United States
  • DURECT Study Site 24
    Arcadia, California 91007, United States
  • Durect Study Site 15
    Fontana, California 92335, United States
  • Durect Study Site 02
    Laguna Hills, California 92653, United States
  • Durect Study Site 18
    Laguna Hills, California 92653, United States
  • Durect Study Site 22
    Pensacola, Florida 32503, United States
  • Durect Study Site 12
    Indianapolis, Indiana 46202, United States
  • Durect Study Site 21
    Royal Oak, Michigan 48073, United States
  • Durect Study Site 17
    Jackson, Mississippi 39202, United States
  • Durect Study Site 16
    Las Vegas, Nevada 89104, United States
  • Durect Study Site 20
    Las Vegas, Nevada 89109, United States
  • Durect Study Site 05
    Stony Brook, New York 11794, United States
  • Durect Study Site 13
    Durham, North Carolina 27710, United States
  • Durect Study Site 09
    Cleveland, Ohio 44106, United States
  • Durect Study Site 11
    Cleveland, Ohio 44111, United States
  • Durect Study Site 07
    Cleveland, Ohio 44195, United States
  • Durect Study Site 14
    Philadelphia, Pennsylvania 19107, United States
  • Durect Study Site 08
    Houston, Texas 77004, United States
  • DURECT Study Site 01
    Houston, Texas 77043, United States
  • Durect Study Site 23
    Plano, Texas 75093, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jun 2017, 19 months.

Results were first posted in Jul 2021, 4 years 1 month after primary completion. A results delay was requested in May 2018.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2015
First posted
Oct 14, 2015
StartActual
Nov 2015
Primary completionActual
Jun 2017
CompletionActual
Aug 2017
Results delay requested
May 23, 2018
Results first posted
Jul 13, 2021
Last update
Jul 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02574520
Lead sponsor
Durect
Responsible party
Sponsor
First posted
Oct 14, 2015
Start date
Nov 2015
Primary completion
Jun 2017
Completion
Aug 2017
Results posted
Jul 13, 2021
Last update
Jul 13, 2021

Study contacts

Dave Ellis, MD
study director · Durect

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion